scholarly journals Development and validation of circulating tumor cells signatures for papillary thyroid cancer diagnosis: A prospective, blinded, multicenter study

2020 ◽  
Vol 10 (4) ◽  
Author(s):  
Siyuan Xu ◽  
Jingning Cheng ◽  
Bojun Wei ◽  
Yang Zhang ◽  
Yang Li ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Tumor Cells ◽  
Papillary Thyroid Cancer ◽  
Circulating Tumor Cells ◽  
Cancer Diagnosis ◽  
Multicenter Study ◽  
Papillary Thyroid ◽  
Development And Validation

scholarly journals Detection of STRN‐ALK fusion in thyroid nodules with indeterminate cytopathology facilitates papillary thyroid cancer diagnosis

2020 ◽  
Author(s):  
Magdalena Jurkiewicz ◽  
Adela Cimic ◽  
Vundavalli V. Murty ◽  
Jennifer H. Kuo ◽  
Susan Hsiao ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Cancer Diagnosis ◽  
Thyroid Nodules ◽  
Papillary Thyroid

scholarly journals Association Between BRAF V600E Mutation and Recurrence of Papillary Thyroid Cancer

2015 ◽  
Vol 33 (1) ◽  
pp. 42-50 ◽  
Author(s):  
Mingzhao Xing ◽  
Ali S. Alzahrani ◽  
Kathryn A. Carson ◽  
Young Kee Shong ◽  
Tae Yong Kim ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Multicenter Study ◽  
Braf Mutation ◽  
Prognostic Value ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Disease Stage ◽  
Papillary Thyroid ◽  
Recurrence Rates

Purpose To investigate the prognostic value of BRAF V600E mutation for the recurrence of papillary thyroid cancer (PTC). Patients and Methods This was a retrospective multicenter study of the relationship between BRAF V600E mutation and recurrence of PTC in 2,099 patients (1,615 women and 484 men), with a median age of 45 years (interquartile range [IQR], 34 to 58 years) and a median follow-up time of 36 months (IQR, 14 to 75 months). Results The overall BRAF V600E mutation prevalence was 48.5% (1,017 of 2,099). PTC recurrence occurred in 20.9% (213 of 1,017) of BRAF V600E mutation–positive and 11.6% (125 of 1,082) of BRAF V600E mutation–negative patients. Recurrence rates were 47.71 (95% CI, 41.72 to 54.57) versus 26.03 (95% CI, 21.85 to 31.02) per 1,000 person-years in BRAF mutation–positive versus –negative patients (P < .001), with a hazard ratio (HR) of 1.82 (95% CI, 1.46 to 2.28), which remained significant in a multivariable model adjusting for patient sex and age at diagnosis, medical center, and various conventional pathologic factors. Significant association between BRAF mutation and PTC recurrence was also found in patients with conventionally low-risk disease stage I or II and micro-PTC and within various subtypes of PTC. For example, in BRAF mutation–positive versus –negative follicular-variant PTC, recurrence occurred in 21.3% (19 of 89) and 7.0% (24 of 342) of patients, respectively, with recurrence rates of 53.84 (95% CI, 34.34 to 84.40) versus 19.47 (95% CI, 13.05 to 29.04) per 1,000 person-years (P < .001) and an HR of 3.20 (95% CI, 1.46 to 7.02) after adjustment for clinicopathologic factors. BRAF mutation was associated with poorer recurrence-free probability in Kaplan-Meier survival analyses in various clinicopathologic categories. Conclusion This large multicenter study demonstrates an independent prognostic value of BRAF V600E mutation for PTC recurrence in various clinicopathologic categories.

scholarly journals Long-term Recurrence of Small Papillary Thyroid Cancer and Its Risk Factors in a Korean Multicenter Study

2016 ◽  
pp. jc.2016-2287 ◽  
Author(s):  
Yul Hwangbo ◽  
Jung Min Kim ◽  
Young Joo Park ◽  
Eun Kyung Lee ◽  
You Jin Lee ◽  
...  
Keyword(s):  
Risk Factors ◽  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Multicenter Study ◽  
Papillary Thyroid

scholarly journals PO-371 Contribution of elevated miR-146b-5p to papillary thyroid cancer diagnosis and development

2018 ◽  
Author(s):  
A Al-Abdallah ◽  
I Jahanbani ◽  
H Mehdawi ◽  
R Ali ◽  
N Al-Brahim ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Cancer Diagnosis ◽  
Papillary Thyroid

Changing the Cancer Diagnosis: The Case of Follicular Variant of Papillary Thyroid Cancer—Primum Non Nocere and NIFTP

Thyroid ◽  
2016 ◽  
Vol 26 (7) ◽  
pp. 869-871 ◽  
Author(s):  
Steven Hodak ◽  
R. Michael Tuttle ◽  
Guy Maytal ◽  
Yuri E. Nikiforov ◽  
Gregory Randolph
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Cancer Diagnosis ◽  
Papillary Thyroid ◽  
Follicular Variant
Sign in / Sign up

Export Citation Format

Share Document